Cardiff Oncology Inc (NASDAQ:CRDF) does about 1.54M shares in volume on a normal day but saw 2733962 shares change hands in Friday trading. The company now has a market cap of 261.38M USD. Its current market price is $5.85, marking an increase of 13.81% compared to the previous close of $5.14. The 52 week high reached by this stock is $6.06 whilst the lowest price level in 52 weeks is $0.94.
Cardiff Oncology Inc (CRDF) has a 20-day trading average at $3.95 and the current price is -3.47% off the 52-week high compared with 522.34% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.56 and its 200-day simple moving average is $1.74. If we look at the stock’s price movements over the week, volatility stands at 16.40%, which increases to 18.09% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 78.83 to suggest the stock is overbought.
The consensus objective for the share price is $10.50, suggesting that the stock has a potential upside of 44.29% over the period.
Maxim Group resumed its price target at $30-$20.
Cardiff Oncology Inc (CRDF) stock is up 16.30% over the week and 246.15% over the past month. Its price is 295.27% year-to-date and 270.25% over the past year.
The stock last released its quarterly earnings report for quarter ended 12/30/2023, with the company’s earnings per share (EPS) of -$0.21 above consensus estimates by $0.07. CRDF’s earnings per share are forecast to shrink by -4.30% this year and -8.20% over next year. Expected sales for next quarter are $60k, which analysts say will come at $240k for the current fiscal year and next year at $70k. In addition, estimates put the company’s current quarterly revenue at an average of $50k.
To reach the target analysts have set, the stock logically needs to grow 44.29 percent from here.
Outstanding shares total 44.68M with insiders holding 7.56% of the shares and institutional holders owning 15.17% of the company’s common stock. The company has a return on investment of -58.24% and return on equity of -47.07%. The beta has a value of 1.90. Price to book ratio is 3.75 and price to sales ratio is 533.42.
